BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Treatment
2042 results:

  • 1. Women's Knowledge of Genomic Testing and Precision Medicine in breast cancer treatment Decision-Making.
    Robles-Rodriguez E; Houser L; Sanchez B; Ormerod C; Washburn S; Oertle SK; Jerome-D'Emilia B
    Oncol Nurs Forum; 2024 Apr; 51(3):199-208. PubMed ID: 38668907
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Factors impacting quality of life for breast cancer survivors.
    Davis SC; Snyder E
    Nurse Pract; 2024 May; 49(5):17-23. PubMed ID: 38662491
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Postpartum breast cancer and Survival in Women With Germline BRCA Pathogenic Variants.
    Zhang Z; Ye S; Bernhardt SM; Nelson HD; Velie EM; Borges VF; Woodward ER; Evans DGR; Schedin PJ
    JAMA Netw Open; 2024 Apr; 7(4):e247421. PubMed ID: 38639936
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. A Study on the Retrospective Reinterpretation of brca1 and BRCA2 Variants.
    Kim JJ; Kim DJ; Nam EJ; Song KE; Ham JY; Kim YK; Lee NY
    Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623660
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Genetic interactions reveal distinct biological and therapeutic implications in breast cancer.
    Lin CJ; Jin X; Ma D; Chen C; Ou-Yang Y; Pei YC; Zhou CZ; Qu FL; Wang YJ; Liu CL; Fan L; Hu X; Shao ZM; Jiang YZ
    Cancer Cell; 2024 Apr; 42(4):701-719.e12. PubMed ID: 38593782
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations.
    Schouten PC; Schmidt S; Becker K; Thiele H; Nürnberg P; Richters L; Ernst C; Treilleux I; Medioni J; Heitz F; Pisano C; Garcia Y; Petru E; Hietanen S; Colombo N; Vergote I; Nagao S; Linn SC; Pujade-Lauraine E; Ray-Coquard I; Harter P; Hahnen E; Schmutzler RK
    JAMA Netw Open; 2024 Apr; 7(4):e245552. PubMed ID: 38592722
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Selective impact of ALK and MELK inhibition on ERα stability and cell proliferation in cell lines representing distinct molecular phenotypes of breast cancer.
    Bartoloni S; Pescatori S; Bianchi F; Cipolletti M; Acconcia F
    Sci Rep; 2024 Apr; 14(1):8200. PubMed ID: 38589728
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Olaparib not cost-effective as maintenance therapy for platinum-sensitive, brca1/2 germline-mutated metastatic pancreatic cancer.
    Mehra T; Lupatsch JE; Kössler T; Dedes K; Siebenhüner AR; von Moos R; Wicki A; Schwenkglenks ME
    PLoS One; 2024; 19(4):e0301271. PubMed ID: 38573891
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Causal association between complement system FHR-5, CTRP9, and breast carcinoma in situ: a Mendelian randomization study.
    Peng YL; Li H; Sun P; Zhang HD; Li D; Wang HB; Zhang L
    Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2363-2371. PubMed ID: 38567599
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area.
    Wu Z; Zhang Q; Jin Y; Zhang X; Chen Y; Yang C; Tang X; Jiang H; Wang X; Zhou X; Yu F; Wang B; Guan M
    BMC Cancer; 2024 Apr; 24(1):411. PubMed ID: 38566028
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report.
    Powers CM; Verma H; Orloff J; Piontkowski AJ; Tiersten A; Lamb A; Gulati N
    J Dermatolog Treat; 2024 Dec; 35(1):2336118. PubMed ID: 38565207
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Difficulties of gender affirming treatment in trans women with brca1+ mutation: A case report.
    Piñar-Gutiérrez A; Dueñas Disotuar S; de Lara-Rodríguez I; Amuedo-Domínguez S; González-Cejudo C; Tejero-Delgado J; Mangas-Cruz MÁ
    Endocrinol Diabetes Nutr (Engl Ed); 2024 Mar; 71(3):144-148. PubMed ID: 38555112
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. cancer trend and radiotherapy utilization at a tertiary academic hospital in Malaysia.
    Gan DEH; Bustam AZ
    J Cancer Res Ther; 2024 Jan; 20(1):358-362. PubMed ID: 38554346
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. A Novel Inhibitor of Poly(
    Jin Y; Wang L; Jin C; Zhang N; Shimizu S; Xiao W; Guo C; Liu X; Si H
    Chem Res Toxicol; 2024 Apr; 37(4):561-570. PubMed ID: 38534178
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Withaferin A alters the expression of microRNAs 146a-5p and 34a-5p and associated hub genes in MDA-MB-231 cells.
    Shuaib M; Chaudhri S; Kumar S
    Biomol Concepts; 2024 Jan; 15(1):. PubMed ID: 38525814
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Somatic mutations in four novel genes contribute to homologous recombination deficiency in breast cancer: a real-world clinical tumor sequencing study.
    Huang Y; Qiu Y; Ding L; Ren S; Jiang Y; Luo J; Huang J; Yin X; Fu S; Zhao J; Hu K; Liao J
    J Pathol Clin Res; 2024 Mar; 10(2):e12367. PubMed ID: 38504382
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Aryl hydrocarbon receptor suppresses STING-mediated type I IFN expression in triple-negative breast cancer.
    Martin JC; da Silva Fernandes T; Chaudhry KA; Oshi M; Abrams SI; Takabe K; Rosario SR; Bianchi-Smiraglia A
    Sci Rep; 2024 Mar; 14(1):5731. PubMed ID: 38459088
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. cancer genetic counselling for hereditary breast cancer in the era of precision oncology.
    Pensabene M; Calabrese A; von Arx C; Caputo R; De Laurentiis M
    Cancer Treat Rev; 2024 Apr; 125():102702. PubMed ID: 38452709
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Abrogation of KLF5 sensitizes
    Zhang Z; Liu Y; Xu Y; Xu Z; Jia J; Jin Y; Wang W; Liu L
    Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(4):576-585. PubMed ID: 38433576
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Impact of breast surgical procedure on survival in BRCA mutated patients with invasive breast cancer: Mastectomy versus conservative treatment.
    Mahiou K; Jankowski C; Vincent L; Costaz H; Padeano MM; Mamguem A; Dabakuyo S; Coutant C
    J Gynecol Obstet Hum Reprod; 2024 May; 53(5):102760. PubMed ID: 38428460
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 103.